Bayesian Capital Management’s Revolution Medicines RVMD Stock Holding History

Bayesian Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,200	Closed	-$599K	–	955
2024 Q3	$599K	Buy	+13,200	New	+$575K	0.07%	339
2024 Q2	–	Sell	-10,500	Closed	-$338K	–	1051
2024 Q1	$338K	Buy	+10,500	New	+$311K	0.03%	529
2023 Q4	–	Sell	-10,432	Closed	-$289K	–	993
2023 Q3	$289K	Buy	+10,432	New	+$309K	0.03%	476
2023 Q2	–	Sell	-28,700	Closed	-$622K	–	1026
2023 Q1	$622K	Buy	+28,700	New	+$707K	0.08%	334
2022 Q4	–	Sell	-10,000	Closed	-$197K	–	1001
2022 Q3	$197K	Sell	10,000 -6,601	-40%	-$145K	0.04%	522
2022 Q2	$324K	Buy	+16,601	New	+$323K	0.06%	453

Other funds holding RVMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bayesian Capital Management's RVMD Position: Q4 2024 in Review

Bayesian Capital Management sold out of Revolution Medicines (RVMD) in Q4 2024, closing a stake of 13,200 shares — an estimated $599K sold.

Bayesian Capital Management first reported a position in RVMD in Q2 2022 and held it in 6 quarters. The position peaked at $622K in Q1 2023. 281 funds tracked by Wall St. Rank hold RVMD as of Q4 2024.

Bayesian Capital Management reported no remaining Revolution Medicines position as of Q4 2024 after selling out during the quarter.
Bayesian Capital Management sold 13,200 Revolution Medicines shares in Q4 2024, an estimated $599K.
Bayesian Capital Management first reported a position in Revolution Medicines in Q2 2022 and held it in 6 quarters.
Bayesian Capital Management's Revolution Medicines position peaked at $622K in Q1 2023.
281 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.